DiaMedica Therapeutics (NASDAQ:DMAC) Now Covered by Analysts at Craig Hallum

Craig Hallum assumed coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report report published on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Separately, Oppenheimer restated an outperform rating and set a $6.00 price objective (down from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st.

DiaMedica Therapeutics Trading Up 1.6 %

NASDAQ DMAC opened at $2.57 on Wednesday. DiaMedica Therapeutics has a 12 month low of $1.53 and a 12 month high of $4.75. The company’s 50-day moving average price is $2.78 and its 200-day moving average price is $2.70. The stock has a market cap of $97.56 million, a PE ratio of -4.15 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Wednesday, March 20th. The company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). As a group, sell-side analysts forecast that DiaMedica Therapeutics will post -0.69 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Paragon Associates & Paragon Associates II Joint Venture lifted its position in DiaMedica Therapeutics by 6.4% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after purchasing an additional 30,000 shares during the period. Stonebridge Capital Advisors LLC purchased a new stake in shares of DiaMedica Therapeutics in the third quarter worth about $52,000. Finally, Avantax Advisory Services Inc. acquired a new stake in DiaMedica Therapeutics during the fourth quarter worth about $36,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.